阿斯利康AstraZeneca plc (AZN) 2006年年度报告「LSE」.pdf

1、ANNUAL REPORT 2006AND FORM 20-F INFORMATIONCONTENTS2006 IN BRIEF 1CHAIRMANS STATEMENT 2CHIEF EXECUTIVE OFFICERS REVIEW 3FINANCIAL HIGHLIGHTS 6DIRECTORS REPORTBusiness review 8 Business environment 9 Strategy 11 Our resources,skills and capabilities 12 Measuring performance 15 Therapy area review Car

2、diovascular medicines 16 Gastrointestinal medicines 20 Neuroscience medicines 23 Oncology medicines 26 Respiratory and Infl ammation medicines 29 Infection medicines 32 Geographic review 33 Research and development 37 Development pipeline table 40 Portfolio management and commercialisation 43 Supply

3、 44 Managing risk 45 Corporate responsibility 47 People 48 Main facilities 49 Other businesses 49 Industry regulation 50 Reporting performance 52 Financial review 53Governance 71 Board of Directors 71 Corporate governance 75 CEO,SET and delegationof authority 77 Other matters 78Board of Directors 80

4、DIRECTORS REMUNERATION REPORT 82FINANCIAL STATEMENTSPreparation of the Financial Statements and Directors Responsibilities 96Directors Responsibilities for,and Report on,Internal Control over FinancialReporting 96Auditors Reports on the Financial Statements and on Internal Control over Financial Rep

5、orting(Sarbanes-Oxley Act Section 404)97Independent Auditors Report to the Members of AstraZeneca PLC(Group)97Consolidated Income Statement 98Consolidated Statement of Recognised Income and Expense 98Consolidated Balance Sheet 99Consolidated Cash Flow Statement 100Accounting Policies(Group)101Notes

6、to the Financial Statements(Group)1.Operating profi t 104 2.Profi t on sale of interest in joint venture 104 3.Finance income and expense 105 4.Taxation 105 5.Earnings per$0.25 OrdinaryShare 107 6.Segment information 108 7.Property,plant and equipment 110 8.Intangible assets 111 9.Other investments